RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide...
Enregistré dans:
Auteurs principaux: | Chae Eun Kim, Hynda K. Kleinman, Gabriel Sosne, George W Ousler, Kyeongsoon Kim, Sinwook Kang, Jaewook Yang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/209b22d9f1ca4439aacdcb974310bacf |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
par: Sosne G, et autres
Publié: (2015) -
Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse
par: Hyesook Lee, et autres
Publié: (2017) -
The interblink interval in normal and dry eye subjects
par: Johnston PR, et autres
Publié: (2013) -
The challenge of dry eye diagnosis
par: Giacomo Savini, et autres
Publié: (2008) -
Automated grading system for evaluation of ocular redness associated with dry eye
par: Rodriguez JD, et autres
Publié: (2013)